FibroGen, Inc
FGEN Real Time Price USDRecent trades of FGEN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by FGEN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
FGEN Revenue by Segment or Geography
New patents grants
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
-
Patent Title: Methods for treatment of motor neuron diseases Apr. 12, 2022
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jan. 25, 2022
-
Patent Title: Enhanced erythropoiesis and iron metabolism Feb. 23, 2021
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 19, 2021
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 05, 2021
-
Patent Title: Pharmaceutical formulations of a hif hydroxylase inhibitor Sep. 08, 2020
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 12, 2020
-
Patent Title: Methods for treating idiopathic pulmonary fibrosis Feb. 11, 2020
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 30, 2019
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 06, 2018
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Oct. 09, 2018
-
Patent Title: Methods for treating idiopathic pulmonary fibrosis Aug. 07, 2018
-
Patent Title: Enhanced erythropoiesis and iron metabolism Mar. 20, 2018
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Mar. 20, 2018
-
Patent Title: Compounds and methods for treatment of stroke Oct. 03, 2017
-
Patent Title: Process for making isoquinoline compounds Jul. 18, 2017
-
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Jul. 04, 2017
-
Patent Title: Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid May. 09, 2017
-
Patent Title: Therapeutic method for pancreatic cancer Apr. 25, 2017
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 11, 2017
-
Patent Title: Treatment method for lung remodeling diseases Mar. 07, 2017
-
Patent Title: Methods for treating idiopathic pulmonary fibrosis Nov. 01, 2016
-
Patent Title: 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors Aug. 09, 2016
-
Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Jul. 12, 2016
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Jun. 21, 2016
-
Patent Title: Process for making isoquinoline compounds May. 17, 2016
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 17, 2016
-
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Mar. 01, 2016
-
Patent Title: Cyanoisoquinoline compounds and methods of use thereof Nov. 03, 2015
-
Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Oct. 06, 2015
-
Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 25, 2015
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Aug. 25, 2015
-
Patent Title: Therapeutic method Aug. 11, 2015
-
Patent Title: Connective tissue growth factor antibodies May. 19, 2015
-
Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 07, 2015
-
Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Feb. 10, 2015
-
Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Jan. 06, 2015
-
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Dec. 30, 2014
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Dec. 23, 2014
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 11, 2014
-
Patent Title: Treatments for pancreatic cancer metastases Oct. 21, 2014
-
Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 12, 2014
-
Patent Title: Methods for treatment of muscular dystrophy Jul. 08, 2014
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jul. 01, 2014
-
Patent Title: Cyanoisoquinoline compounds and methods of use thereof Jun. 24, 2014
-
Patent Title: Treatments for cancer May. 20, 2014
-
Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 22, 2014
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 14, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to FGEN
Recent picks made for FGEN stock on CNBC
ETFs with the largest estimated holdings in FGEN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $FGEN stock a Buy, Sell, or Hold?
- What is the price target for $FGEN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $FGEN stock?
- Who owns the most shares of $FGEN stock?
- What funds own $FGEN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view FGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.